Packer M., Januzzi JL., Ferreira JP, et al. - This study was designed to evaluate the concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin. Researchers designed an EMPEROR-Reduced trial randomizing patients with class II-IV heart failure and a reduced ejection fraction to placebo or empagliflozin 10 mg daily and followed for the occurrence of serious heart failure and renal events. They assessed high-sensitivity cardiac troponin T (hs-cTnT) in 3,636 patients (> 97%) at baseline, and individuals were classified into four groups based on the degree of troponin elevation. This study’s findings demonstrate that elevations in hs-cTnT reflect the clinical severity, stability, and prognosis of patients with heart failure and a reduced ejection fraction, with biomarkers, comorbidities, clinical course, and risks that are proportional to the magnitude of hs-cTnT elevation. The data demonstrate that empagliflozin exerted favorable effects on heart failure and renal outcomes, regardless of the baseline concentration of hs-cTnT.